Posts Tagged ‘advanced prostate cancer’

Risk of Aggressive Prostate Cancer linked to Common Sexual Infection

Wednesday, September 30th, 2009

logo1267406_md2
A new study from the Harvard School of Public Health and Brigham and Women’s Hospital reported on the September 9, 2009 Journal of the National Cancer Institute website reported a strong association between Trichomonas vaginalis, a common sexually transmitted infection, and the risk of advanced and lethal prostate cancer in men.
An important risk factor for prostate cancer is inflammation but the source has been unclear. Trichomonas vaginalis can infect the prostate and may be the source of inflammation.

A previous study found an association between Trichomonas Vaginalis infection and prostate cancer but was too small to determine if there was a link between the infection and advanced and lethal prostate disease. In the current stuidy researchers analyzed the blood samples from 673 men with prostate cancer and compared infection status based upon antibody levels with 673 control subjects who were not diagnosed with prostate cancer. The samples of blood were collected in 1982, on an average a decade before the cancer diagnoses.
Results showed that Trichomonas vaginalis infection was associated with over a two fold increase risk of prostate cancer that was at an advanced stage at diagnoses and a nearly three-fold increase in prostate cancer that would result in death. Further research is needed.

Advanced Prostate Cancer Treated Sucessfully with Immune Boosting Drug, Ipilimimab

Wednesday, June 24th, 2009

DRAMATIC RESULTS FOR PROSTATE CANCER SURVIVORS WITH EXPERIMENTAL IMMUNE BOOSTING DRUG, IPILIMIMAB

TWO MEN DIAGNOSED WITH ADVANCED AND INOPERABLE PROSTATE CANCER RECOVERED AFTER BEING TREATED WITH AN EXPERIMENTAL ANTIBODY DRUG, IPILIMUMAB THAT BOOSTS THE IMMUNE SYSTEM. . BOTH ARE CANCER FREE AND HAVE RETURNED TO NORMAL LIFE.. THE GOAL OF THE STUDY AT THE MAYO CLINIC IN ROCHESTER, MINNESOTA WAS TO SEE IF THEY COULD IMPROVE UPON CURRENT TREATMENT FOR ADVANCED PROSTATE CANCER AND SUBJECTS IN THE STUDY WERE PEOPLE WHO DID NOT HAVE MANY OPTIONS BECAUSE OF THE ADVANCEMENT OF THE DISEASE. THE TREATMENT PROCESS WAS AS FOLLOWS: 1) PATIENTS RECEIVED TRADITIONAL HORMONAL THERAPY TO REMOVE TESTERONE, WHICH FUELS PROSTATE CANCER. 2) RESEARCHERS INTRODUCED A SINGLE DOSE OF IPILIMUMAB. FOLLOWING HORMONAL TREATMENT BOTH PATIENTS SAW THEIR PSA DROP TO A POINT WHERE THEY WERE ELIGIBLE FOR SURGERY. WHEN THE SURGEONS MADE THEIR INCISION THEY FOUND THE CANCER HAD SHRUNK DRAMATICALLY AND HAD DIFFICULTY FINDING IT. ONE PATIENT ALSO HAD RADIATION THERAPY AFTER THE SURGERY. FURTHER RESEARCH IS PLANNED.
A SECOND